Cargando…

Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment

Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG-PET, because the immune response recalls reactiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Oriuchi, Noboru, Endoh, Hideki, Kaira, Kyoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409366/
https://www.ncbi.nlm.nih.gov/pubmed/36012657
http://dx.doi.org/10.3390/ijms23169394
_version_ 1784774833649745920
author Oriuchi, Noboru
Endoh, Hideki
Kaira, Kyoichi
author_facet Oriuchi, Noboru
Endoh, Hideki
Kaira, Kyoichi
author_sort Oriuchi, Noboru
collection PubMed
description Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG-PET, because the immune response recalls reactive cells such as activated T-cells and macrophages, which show increased glucose metabolism and apparent progression on morphological imaging. Cellular metabolism and function are critical determinants of the viability of active cells in the tumor microenvironment, which would be novel targets of therapies, such as tumor immunity, metabolism, and genetic mutation. Considering tumor heterogeneity and variation in therapy response specific to the mechanisms of therapy, appropriate response evaluation is required. Radiomics approaches, which combine objective image features with a machine learning algorithm as well as pathologic and genetic data, have remarkably progressed over the past decade, and PET radiomics has increased quality and reliability based on the prosperous publications and standardization initiatives. PET and multimodal imaging will play a definitive role in personalized therapeutic strategies by the precise monitoring in future cancer therapy.
format Online
Article
Text
id pubmed-9409366
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94093662022-08-26 Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment Oriuchi, Noboru Endoh, Hideki Kaira, Kyoichi Int J Mol Sci Review Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG-PET, because the immune response recalls reactive cells such as activated T-cells and macrophages, which show increased glucose metabolism and apparent progression on morphological imaging. Cellular metabolism and function are critical determinants of the viability of active cells in the tumor microenvironment, which would be novel targets of therapies, such as tumor immunity, metabolism, and genetic mutation. Considering tumor heterogeneity and variation in therapy response specific to the mechanisms of therapy, appropriate response evaluation is required. Radiomics approaches, which combine objective image features with a machine learning algorithm as well as pathologic and genetic data, have remarkably progressed over the past decade, and PET radiomics has increased quality and reliability based on the prosperous publications and standardization initiatives. PET and multimodal imaging will play a definitive role in personalized therapeutic strategies by the precise monitoring in future cancer therapy. MDPI 2022-08-20 /pmc/articles/PMC9409366/ /pubmed/36012657 http://dx.doi.org/10.3390/ijms23169394 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Oriuchi, Noboru
Endoh, Hideki
Kaira, Kyoichi
Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
title Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
title_full Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
title_fullStr Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
title_full_unstemmed Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
title_short Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
title_sort monitoring of current cancer therapy by positron emission tomography and possible role of radiomics assessment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409366/
https://www.ncbi.nlm.nih.gov/pubmed/36012657
http://dx.doi.org/10.3390/ijms23169394
work_keys_str_mv AT oriuchinoboru monitoringofcurrentcancertherapybypositronemissiontomographyandpossibleroleofradiomicsassessment
AT endohhideki monitoringofcurrentcancertherapybypositronemissiontomographyandpossibleroleofradiomicsassessment
AT kairakyoichi monitoringofcurrentcancertherapybypositronemissiontomographyandpossibleroleofradiomicsassessment